Bicycle Therapeutics (NASDAQ: BCYC)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-04 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.680 | -0.930 | -0.2500 | ||||
REV | 4.410M | 3.860M | -550.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Bicycle Therapeutics (NASDAQ: BCYC) through any online brokerage.
Other companies in Bicycle Therapeutics’s space includes: Immunovant (NASDAQ:IMVT), IDEAYA Biosciences (NASDAQ:IDYA), Kezar Life Sciences (NASDAQ:KZR), Centessa Pharmaceuticals (NASDAQ:CNTA) and Altimmune (NASDAQ:ALT).
The latest price target for Bicycle Therapeutics (NASDAQ: BCYC) was reported by Piper Sandler on Monday, May 23, 2022. The analyst firm set a price target for 37.00 expecting BCYC to rise to within 12 months (a possible 111.55% upside). 13 analyst firms have reported ratings in the last year.
The stock price for Bicycle Therapeutics (NASDAQ: BCYC) is $17.49 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Bicycle Therapeutics.
Bicycle Therapeutics’s Q2 earnings are confirmed for Thursday, August 4, 2022.
There is no upcoming split for Bicycle Therapeutics.
Bicycle Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.